Clinical trials: Treatment Resistant
Treatment Resistant Depression
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
The purpose of this study is to determine if CX157 is effective and safe in patients with treatment of treatment resistant depression over six weeks of treatment.
- Trial name
- CX157-201 (NCT01246908)
- Testing
- CX157 (TriRima)
- Where
- 30 sites in United States
- Volunteers
- 360 people
- Sponsor
- CeNeRx BioPharma Inc.
Major Depressive Disorder, Treatment Resistant Depression
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an…
- Trial name
- RUBY (NCT00789854)
- Testing
- Quetiapine XR, Lithium carbonate, SSRI/Venlafaxine
- Where
- 106 sites in Australia, Austria and 11 more
- Volunteers
- 688 people
- Sponsor
- AstraZeneca
Healthy
A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCI-838 and its metabolite BCI-632 in healthy male and female subjects.
- Trial name
- NCT01548703
- Testing
- BCI-838
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Major Depression
Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression
This pilot study will assess the efficacy of several sequential pharmacological treatments for patients with Refractory Depression.
- Trial name
- NCT00296686
- Testing
- Tranylcypromine, Dextroamphetamine, Triiodothyronine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- New York State Psychiatric Institute
Depression
Effectiveness of Pramipexole for Treatment-Resistant Depression
This study will evaluate the effectiveness of pramipexole (Mirapex) in managing treatment-resistant depression.
- Trial name
- NCT00231959
- Testing
- Pramipexole (Mirapex)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Healthy
A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers
This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its metabolite BCI-632 and several new pro-drugs in healthy male subjects.
- Trial name
- NCT01546051
- Testing
- BCI-838, BCI-1038, BCI-1206 & BCI-1283
- Where
- Netherlands
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis
Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis
The purpose of this study is to determine whether nalfurafine hydrochloride is effective and safe in the treatment for conventional-treatment-resistant pruritus in patients receiving hemodialysis.
- Trial name
- TRK-820 (NCT01513161)
- Testing
- nalfurafine hydrochloride (TRK-820)
- Where
- South Korea
- Volunteers
- 104 people
- Sponsor
- SK Chemicals Co., Ltd.
Depression, Major Depressive Disorder
Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study
The purpose of this study is to determine whether an oxytocin ad-on, or oxytocin and tibolone ad-on can induce a response to antidepressants in patients with treatment resistant depression.
- Trial name
- NCT01239888
- Testing
- Oxytocin, Oxytocin and Tibolone
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- The Alfred
Refractory Schizophrenia
Repetitive Transcranial Magnetic Stimulation for Refractory Auditory Hallucinations in Schizophrenia
Studies using repetitive transcranial magnetic stimulation (rTMS) as a treatment for refractory auditory hallucinations (AH) in schizophrenia have shown promise.
- Trial name
- NCT01386918
- Testing
- repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 144 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment-Resistant Depression Disease
Sequential Left Prefrontal Repetitive Transcranial Magnetic Stimulation, With High Frequency, for Treatment-Resistant Depression
Sequential left prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS), with high frequency, for Treatment-Resistant Depression have been shown to have antidepressant effects.
- Trial name
- NCT01469325
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Tehran University of Medical Sciences
Depression, Major Depression
Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients
The purpose of this study is to evaluate three different continuation treatments after acute ECT concerning efficacy and impact on cognition in severly depressed patients.
- Trial name
- EffECT (NCT00437385)
- Testing
- TCAs, SSRIs, NARIs, SNRIs, Lithium, Electroconvulsive therapy, Cognitive behavioral group therapy
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Charite University, Berlin, Germany
Treatment Resistant Depression
Deep Brain Stimulation in Treatment Resistant Depression
Recurrent major depressive disorder affects about 3-5% of the population. It is anticipated that by 2020, depression will be the most common cause of disability worldwide in the 18-55 age group.
- Trial name
- NCT01435148
- Testing
- Deep Brain Stimulation, implanted
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- North Bristol NHS Trust
Treatment Resistant Depression
Ketamine Frequency Treatment for Major Depressive Disorder
Depression is a wide spread illness. Depression contributes most significantly to national health care costs. While the number and types of treatments used for depression have expanded over the years, even with an increased range…
- Trial name
- NCT00646087
- Testing
- Ketamine, Ketamine/Saline
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Essentia Health
Subjects Had Unipolar, Non-psychotic Major Depression
Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression
Atypical neuroleptics may have antidepressant qualities in bipolar depression and in unipolar depression. Some data support the use of both Risperidone and Olanzapine, but there are no direct comparisons of their relative…
- Trial name
- NCT01282632
- Testing
- Risperidone, Olanzapine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Sunnybrook Health Sciences Centre
Schizophrenia, Auditory Hallucinations
A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine
The primary outcome of this study is to evaluate the effects of low frequency subthreshold repetitive Transcranial Magnetic Stimulation applied to the left temporoparietal cortex of patients with refractory schizophrenia on the…
- Trial name
- NCT01015001
- Testing
- (1Hz) rTMS applied over the left temporoparietal cortex
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Treatment-resistant Schizophrenia
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients
This study includes two main components: the first screening phase and the second clinical intervention phase. During the screening phase, subjects with poor response to clozapine are carefully evaluated by chart-review and…
- Trial name
- M1106 (NCT01105481)
- Testing
- Amisulpride add-on
- Where
- 2 sites in Taiwan
- Volunteers
- 273 people
- Sponsor
- National Health Research Institutes, Taiwan
Depression, Depressive Disorder
Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and effectiveness of cortical stimulation to the cerebral cortex of subjects who have suffered from treatment-resistant depression and have failed routine attempts at controlling…
- Trial name
- PROSPECT (NCT00380042)
- Testing
- Cortical Stimulation
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northstar Neuroscience
Depression
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
STAR*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication…
- Trial name
- NCT00021528
- Testing
- citalopram, BuproprionSR, buspirone
- Where
- 41 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- National Institute of Mental Health (NIMH)
Weight Gain, Sialorrhea
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or…
- Trial name
- FOCUS (NCT00683891)
- Testing
- FazaClo (clozapine, USP) ODT
- Where
- 2 sites in United States
- Sponsor
- Azur Pharma, Inc